<p>Coherus Oncology, Inc.（纳斯达克代码：CHRS - 获取免费报告）的股票在目前覆盖该公司的五位分析师中获得了 “持有” 的共识评级，Marketbeat Ratings 报告称。一位研究分析师给予该股票卖出评级，一位给予持有评级，三位则对该公司给予买入评级。在过去一年中，给予该股票评级的分析师的平均 12 个月目标价格为 4.0167 美元。</p>
<p>获取 <strong>Coherus Oncology</strong> 警报：</p>
<p>几位股票分析师对该公司发布了报告。华尔街禅在 11 月 8 日的研究报告中将 Coherus Oncology 的评级从 “卖出” 上调至 “持有”。Oppenheimer 在周四的研究报告中开始覆盖 Coherus Oncology，并对该股票给予了 “跑赢大盘” 的评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Coherus Oncology 股票的 “卖出（d）” 评级。</p>
<p><strong>查看我们最新的 CHRS 股票报告</strong></p>
<h2>Coherus Oncology 股票下跌 3.0%</h2>
<p>Coherus Oncology 股票在周四的午盘交易中下跌 0.05 美元，报 1.59 美元。该公司的交易量为 2,770,077 股，而其平均交易量为 1,605,373 股。该公司的速动比率为 1.23，流动比率为 1.24，债务与股本比率为 0.42。Coherus Oncology 的 1 年最低价为 0.71 美元，1 年最高价为 1.89 美元。该公司的 50 日移动平均价为 1.37 美元，200 日移动平均价为 1.32 美元。该股票的市值为 1.9218 亿美元，市盈率为 1.20，贝塔值为 0.96。</p>
<p>Coherus Oncology（纳斯达克代码：CHRS - 获取免费报告）最近在 11 月 6 日发布了其财报。这家生物技术公司报告本季度每股收益为（0.33 美元），超出市场共识预期的（0.34 美元）0.01 美元。该公司在本季度的收入为 1157 万美元，而分析师的预期为 1341 万美元。卖方分析师平均预计 Coherus Oncology 在当前财年将发布每股收益-1.05 美元。</p>
<h2>对 Coherus Oncology 的对冲基金看法</h2>
<p>几家对冲基金最近增加或减少了在 CHRS 的持股。Strs Ohio 在第一季度以 261,000 美元的估值收购了 Coherus Oncology 的新头寸。Panagora Asset Management Inc.在第二季度以 581,000 美元的估值收购了 Coherus Oncology 的新头寸。International Assets Investment Management LLC 在第二季度以约 33,000 美元的估值购买了 Coherus Oncology 的新头寸。Corient Private Wealth LLC 在第二季度将其在 Coherus Oncology 的持股增加了 20.0%。Corient Private Wealth LLC 现在拥有 60,000 股该生物技术公司的股票，价值 44,000 美元，此前在上个季度又购买了 10,000 股。最后，Voya Investment Management LLC 在第三季度以约 28,000 美元的估值收购了 Coherus Oncology 的新股份。目前 72.82% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Coherus Oncology 公司简介</h2>
<p>（获取免费报告）</p>
<p>Coherus Oncology, Inc 是一家商业阶段的生物制药公司，专注于开发、制造和商业化用于肿瘤支持和免疫肿瘤学的生物治疗。该公司成立于 2010 年，总部位于加利福尼亚州红木城，专注于已建立的肿瘤药物的生物类似药以及新型免疫疗法候选药物。</p>
<p>该公司的主要市场产品包括 Udenyca（pegfilgrastim-cbqv）和 Fulphila（pegfilgrastim-jmdb），这两种药物是 Amgen 的 Neulasta 的生物类似药，旨在减少接受骨髓抑制化疗的患者感染的发生率。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Coherus Oncology</li>
<li>特朗普的 AI 秘密：比 Nvidia 快 100 倍</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
<li>新的黄金价格目标</li>
<li>特朗普计划使用公共法 63-43：现在准备好</li>
<li>你的银行账户不再安全</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0hSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0hSUw"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Coherus Oncology 吗？</h2>
<p>在你考虑 Coherus Oncology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Coherus Oncology 并不在名单上。</p>
<p>虽然 Coherus Oncology 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Coherus Oncology, Inc.（纳斯达克代码：CHRS）获得了五位分析师的 “持有” 共识评级。一位分析师将其评级为卖出，一位为持有，三位为买入。12 个月的平均目标价格为 4.0167 美元。该股票目前下跌 3.0%，交易价格为 1.59 美元，市值为 1.9218 亿美元。Coherus 报告每股收益为（0.33 美元），超出预期，但收入未达标。对冲基金持有该股票的 72.82%。Coherus 专注于肿瘤学的生物类似药治疗</p>

<p>Shares of Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) have received a consensus rating of &#34;Hold&#34; from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $4.0167.</p>
<div class="lb-trans"><p>Coherus Oncology, Inc.（纳斯达克代码：CHRS - 获取免费报告）的股票在目前覆盖该公司的五位分析师中获得了 “持有” 的共识评级，Marketbeat Ratings 报告称。一位研究分析师给予该股票卖出评级，一位给予持有评级，三位则对该公司给予买入评级。在过去一年中，给予该股票评级的分析师的平均 12 个月目标价格为 4.0167 美元。</p>
</div><p>Get <strong>Coherus Oncology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Coherus Oncology</strong> 警报：</p>
</div><p>Several equities analysts have issued reports on the company. Wall Street Zen upgraded Coherus Oncology from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 8th. Oppenheimer initiated coverage on Coherus Oncology in a research note on Thursday. They issued an &#34;outperform&#34; rating on the stock. Finally, Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of Coherus Oncology in a research report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>几位股票分析师对该公司发布了报告。华尔街禅在 11 月 8 日的研究报告中将 Coherus Oncology 的评级从 “卖出” 上调至 “持有”。Oppenheimer 在周四的研究报告中开始覆盖 Coherus Oncology，并对该股票给予了 “跑赢大盘” 的评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Coherus Oncology 股票的 “卖出（d）” 评级。</p>
</div><p><strong>View Our Latest Stock Report on CHRS</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 CHRS 股票报告</strong></p>
</div><h2>Coherus Oncology Stock Down 3.0%</h2>
<div class="lb-trans"><h2>Coherus Oncology 股票下跌 3.0%</h2>
</div><p>Coherus Oncology stock traded down $0.05 during mid-day trading on Thursday, hitting $1.59. The company had a trading volume of 2,770,077 shares, compared to its average volume of 1,605,373. The company has a quick ratio of 1.23, a current ratio of 1.24 and a debt-to-equity ratio of 0.42. Coherus Oncology has a 1 year low of $0.71 and a 1 year high of $1.89. The business has a fifty day moving average of $1.37 and a 200 day moving average of $1.32. The stock has a market cap of $192.18 million, a price-to-earnings ratio of 1.20 and a beta of 0.96.</p>
<div class="lb-trans"><p>Coherus Oncology 股票在周四的午盘交易中下跌 0.05 美元，报 1.59 美元。该公司的交易量为 2,770,077 股，而其平均交易量为 1,605,373 股。该公司的速动比率为 1.23，流动比率为 1.24，债务与股本比率为 0.42。Coherus Oncology 的 1 年最低价为 0.71 美元，1 年最高价为 1.89 美元。该公司的 50 日移动平均价为 1.37 美元，200 日移动平均价为 1.32 美元。该股票的市值为 1.9218 亿美元，市盈率为 1.20，贝塔值为 0.96。</p>
</div><p>Coherus Oncology (NASDAQ:CHRS - Get Free Report) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $11.57 million during the quarter, compared to analysts' expectations of $13.41 million. On average, sell-side analysts expect that Coherus Oncology will post -1.05 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Coherus Oncology（纳斯达克代码：CHRS - 获取免费报告）最近在 11 月 6 日发布了其财报。这家生物技术公司报告本季度每股收益为（0.33 美元），超出市场共识预期的（0.34 美元）0.01 美元。该公司在本季度的收入为 1157 万美元，而分析师的预期为 1341 万美元。卖方分析师平均预计 Coherus Oncology 在当前财年将发布每股收益-1.05 美元。</p>
</div><h2>Hedge Funds Weigh In On Coherus Oncology</h2>
<div class="lb-trans"><h2>对 Coherus Oncology 的对冲基金看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in CHRS. Strs Ohio acquired a new position in Coherus Oncology in the 1st quarter valued at $261,000. Panagora Asset Management Inc. acquired a new position in Coherus Oncology in the second quarter valued at $581,000. International Assets Investment Management LLC purchased a new position in Coherus Oncology during the second quarter worth about $33,000. Corient Private Wealth LLC boosted its stake in Coherus Oncology by 20.0% in the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company's stock worth $44,000 after buying an additional 10,000 shares during the last quarter. Finally, Voya Investment Management LLC acquired a new stake in Coherus Oncology in the 3rd quarter worth about $28,000. 72.82% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了在 CHRS 的持股。Strs Ohio 在第一季度以 261,000 美元的估值收购了 Coherus Oncology 的新头寸。Panagora Asset Management Inc.在第二季度以 581,000 美元的估值收购了 Coherus Oncology 的新头寸。International Assets Investment Management LLC 在第二季度以约 33,000 美元的估值购买了 Coherus Oncology 的新头寸。Corient Private Wealth LLC 在第二季度将其在 Coherus Oncology 的持股增加了 20.0%。Corient Private Wealth LLC 现在拥有 60,000 股该生物技术公司的股票，价值 44,000 美元，此前在上个季度又购买了 10,000 股。最后，Voya Investment Management LLC 在第三季度以约 28,000 美元的估值收购了 Coherus Oncology 的新股份。目前 72.82% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Coherus Oncology Company Profile</h2>
<div class="lb-trans"><h2>Coherus Oncology 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.</p>
<div class="lb-trans"><p>Coherus Oncology, Inc 是一家商业阶段的生物制药公司，专注于开发、制造和商业化用于肿瘤支持和免疫肿瘤学的生物治疗。该公司成立于 2010 年，总部位于加利福尼亚州红木城，专注于已建立的肿瘤药物的生物类似药以及新型免疫疗法候选药物。</p>
</div><p>The company's lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen's Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.</p>
<div class="lb-trans"><p>该公司的主要市场产品包括 Udenyca（pegfilgrastim-cbqv）和 Fulphila（pegfilgrastim-jmdb），这两种药物是 Amgen 的 Neulasta 的生物类似药，旨在减少接受骨髓抑制化疗的患者感染的发生率。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Coherus Oncology</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>New gold price target</li>
<li>Trump Planning to Use Public Law 63-43: Prepare Now</li>
<li>Your Bank Account Is No Longer Safe</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Coherus Oncology</li>
<li>特朗普的 AI 秘密：比 Nvidia 快 100 倍</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
<li>新的黄金价格目标</li>
<li>特朗普计划使用公共法 63-43：现在准备好</li>
<li>你的银行账户不再安全</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0hSUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CHRS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Coherus Oncology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Coherus Oncology 吗？</h2>
</div><p>Before you consider Coherus Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Coherus Oncology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coherus Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Coherus Oncology 并不在名单上。</p>
</div><p>While Coherus Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Coherus Oncology 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts

Market Beat

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

Coherus生物科学

标普全球医疗股指数 ETF - iShares

标普生物技术 ETF - SPDR

基因改革 ETF - ARK

Invesco Nasdaq Biotechnology ETF

美国制药 ETF - iShares

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做空 - Direxion

Coherus 生物科学公司（纳斯达克代码：CHRS）被分析师一致建议为 “持有”